世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

北米の医薬品添加剤市場 - 産業動向と2029年までの予測


North America Pharmaceutical Excipients Market - Industry Trends and Forecast to 2029

北米の医薬品賦形剤市場は、2023年から2030年の予測期間に6.6%の大幅なCAGRを記録すると予測されています。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2022年12月1日 US$3,500
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		144 英語

　

サマリー

北米の医薬品賦形剤市場は、2023年から2030年の予測期間に6.6%の大幅なCAGRを記録すると予測されています。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。
市場の細分化
北米の医薬品添加剤市場、機能性（結合剤・接着剤、崩壊剤、コーティング剤、可溶化剤、香料、甘味料、希釈剤、潤滑剤、緩衝剤、乳化剤、保存料、酸化防止剤、吸着剤、溶剤、エモリエント、滑沢剤、キレート剤、消泡剤、その他）、剤形（固体、半固体、液体）、投与経路（口腔添加物、外用剤、非経口剤、その他の添加剤）、エンドユーザー（製薬・バイオ医薬品会社、受託製剤会社、研究機関・学術機関、その他）、流通チャネル（直接入札、小売販売、その他）地域（中国、インド、日本、韓国、インドネシア、タイ、ベトナム、フィリピン、シンガポール、マレーシア、オーストラリア、その他アジア太平洋）-産業動向と2030年までの予測

北米の賦形剤市場の成長に寄与している主な要因としては、以下のようなものが挙げられます：

- バイオ医薬品の革新的な技術
- 多様な治療領域で高まる医薬品へのニーズ
市場のプレーヤー：

北米の医薬品添加剤市場で事業を展開している主要な市場関係者は以下の通りです：
- DOW
- ロケット フレール
- JRSファーマ
- エボニック・インダストリーズAG
- ルーブリゾール・コーポレーション（The Lubrizol Corporation
- ケリーグループPLC
- カラーコン
- アシュランド
- BASF SE


ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET 14
1.4 LIMITATIONS 16
1.5 MARKETS COVERED 17
2 MARKET SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 21
2.4 CURRENCY AND PRICING 21
2.5 DBMR TRIPOD DATA VALIDATION MODEL 22
2.6 MULTIVARIATE MODELLING 25
2.7 FUNCTIONALITY LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 DBMR MARKET POSITION GRID 28
2.10 MARKET END USER COVERAGE GRID 29
2.11 VENDOR SHARE ANALYSIS 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHT 36
4.1 PESTEL 37
4.2 PORTER'S FIVE FORCES MODEL 38
4.3 INDUSTRIAL INSIGHTS: 39
5 NORTH AMERICA PHARMACEUTICAL EXCIPIENT MARKET: REGULATIONS 41
6 MARKET OVERVIEW 43
6.1 DRIVERS 45
6.1.1 RISE IN GENERIC DRUG PRODUCTION AND USES 45
6.1.2 THE SURGE IN DEMAND FOR EXCIPIENTS 45
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN MULTIFUNCTIONAL EXCIPIENTS 45
6.1.4 RISING FOCUS ON ORPHAN DRUGS 46
6.2 RESTRAINTS 46
6.2.1 INCREASING REGULATORY STRINGENCY REGARDING THE APPROVAL OF DRUGS AND EXCIPIENTS 46
6.2.2 HIGH PRODUCTION COST 47
6.3 OPPORTUNITIES 47
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 47
6.3.2 RISING DEMAND FOR EASE OF USE 48
6.3.3 RISING DISPOSABLE INCOME 48
6.3.4 INCREASING DEMAND FOR ALTERNATIVE ROUTES OF DELIVERY/DOSAGE FORMS 48
6.4 CHALLENGES 49
6.4.1 ASSOCIATED SIDE EFFECTS 49
6.4.2 SAFETY CONSIDERATION OF PHARMACEUTICAL EXCIPIENTS IN STORAGE & TRANSPORTATION 49
6.4.3 LACK OF NOVEL PHARMACEUTICAL EXCIPIENTS 50
7 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY 51
7.1 OVERVIEW 52
7.2 BINDERS AND ADHESIVES 55
7.2.1 ORGANIC 56
7.2.2 INORGANIC 56
7.3 DISINTEGRANTS 56
7.3.1 ORGANIC 56
7.3.2 INORGANIC 57
7.4 COATING MATERIAL 57
7.4.1 ORGANIC 57
7.4.2 INORGANIC 57
7.5 COLORING AGENTS 58
7.5.1 ORGANIC 58
7.5.2 INORGANIC 58
7.6 SOLUBILIZERS 58
7.6.1 ORGANIC 59
7.6.2 INORGANIC 59
7.7 FLAVORS 59
7.7.1 ORGANIC 59
7.7.2 INORGANIC 59
7.8 SWEETENING AGENTS 59
7.8.1 ORGANIC 60
7.8.2 INORGANIC 60
7.9 DILUENTS 60
7.9.1 ORGANIC 60
7.9.2 INORGANIC 60
7.10 LUBRICANTS 61
7.10.1 ORGANIC 61
7.10.2 INORGANIC 61
7.11 BUFFERS 61
7.11.1 ORGANIC 62
7.11.2 INORGANIC 62
7.12 EMULSIFYING AGENTS 62
7.12.1 ORGANIC 62
7.12.2 INORGANIC 62
7.13 PRESERVATIVES 63
7.13.1 ORGANIC 63
7.13.2 INORGANIC 63
7.14 ANTIOXIDANTS 63
7.14.1 ORGANIC 64
7.14.2 INORGANIC 64
7.15 SORBENTS 64
7.15.1 ORGANIC 64
7.15.2 INORGANIC 64
7.16 SOLVENTS 65
7.16.1 ORGANIC 65
7.16.2 INORGANIC 65
7.17 EMOLLIENTS 65
7.17.1 ORGANIC 65
7.17.2 INORGANIC 66
7.18 GLIDENTS 66
7.18.1 ORGANIC 66
7.18.2 INORGANIC 66
7.19 CHELATING AGENTS 66
7.19.1 ORGANIC 67
7.19.2 INORGANIC 67
7.20 ANTIFOAMING AGENTS 67
7.20.1 ORGANIC 67
7.20.2 INORGANIC 67
7.21 OTHERS 68
8 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM 69
8.1 OVERVIEW 70
8.2 SOLID 73
8.2.1 PLANT 73
8.2.2 ANIMALS 73
8.2.3 SYNTHETIC 73
8.2.4 MINERALS 73
8.3 SEMI-SOLID 73
8.3.1 PLANT 74
8.3.2 ANIMALS 74
8.3.3 SYNTHETIC 74
8.3.4 MINERALS 74
8.4 LIQUID 75
8.4.1 PLANT 75
8.4.2 ANIMALS 75
8.4.3 SYNTHETIC 75
8.4.4 MINERALS 75
9 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY ROUTE OF ADMINISTRATION 76
9.1 OVERVIEW 77
9.2 ORAL EXCIPIENTS 80
9.3 TOPICAL EXCIPIENTS 80
9.4 PARENTERAL EXCIPIENTS 80
9.5 OTHER EXCIPIENTS 80
10 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL 81
10.1 OVERVIEW 82
10.2 DIRECT TENDER 85
10.2.1 COMPANY TENDER 85
10.2.2 TENDER THROUGH MARCH MERCHANDISER 85
10.3 RETAIL SALES 85
10.4 OTHERS 85
11 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY END USER 86
11.1 OVERVIEW 87
11.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 90
11.3 CONTRACT FORMULATORS 90
11.4 RESEARCH ORGANIZATION 90
11.5 OTHERS 90
12 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION 91
12.1 U.S. 96
12.2 CANADA 96
12.3 MEXICO 96
13 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY LANDSCAPE 97
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 97
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 98
14 SWOT ANALYSIS 99
15 COMPANY PROFILE 100
15.1 DOW 100
15.1.1 COMPANY SNAPSHOT 100
15.1.2 REVENUE ANALYSIS 100
15.1.3 COMPANY SHARE ANALYSIS 101
15.1.4 PRODUCT PORTFOLIO 101
15.1.5 RECENT DEVELOPMENTS 101
15.2 ROQUETTE FRÈRES. 102
15.2.1 COMPANY SNAPSHOT 102
15.2.2 COMPANY SHARE ANALYSIS 102
15.2.3 PRODUCT PORTFOLIO 103
15.2.4 RECENT DEVELOPMENTS 104
15.3 EVONIK 105
15.3.1 COMPANY SNAPSHOT 105
15.3.2 REVENUE ANALYSIS 105
15.3.3 COMPANY SHARE ANALYSIS 106
15.3.4 PRODUCT PORTFOLIO 106
15.3.5 RECENT DEVELOPMENTS 106
15.4 THE LUBRIZOL CORPORATION 108
15.4.1 COMPANY SNAPSHOT 108
15.4.2 COMPANY SHARE ANALYSIS 108
15.4.3 PRODUCT PORTFOLIO 109
15.4.4 RECENT DEVELOPMENTS 109
15.5 BASF SE 110
15.5.1 COMPANY SNAPSHOT 110
15.5.2 REVENUE ANALYSIS 110
15.5.3 COMPANY SHARE ANALYSIS 111
15.5.4 PRODUCT PORTFOLIO 111
15.5.5 RECENT DEVELOPMENTS 112
15.6 ASHLAND (2021) 114
15.6.1 COMPANY SNAPSHOT 114
15.6.2 REVENUE ANALYSIS 114
15.6.3 PRODUCT PORTFOLIO 115
15.6.4 RECENT DEVELOPMENTS 116
15.7 AVANTOR, INC. 117
15.7.1 COMPANY SNAPSHOT 117
15.7.2 REVENUE ANALYSIS 117
15.7.3 PRODUCT PORTFOLIO 118
15.7.4 RECENT DEVELOPMENTS 119
15.8 BENEO 120
15.8.1 COMPANY SNAPSHOT 120
15.8.2 PRODUCT PORTFOLIO 120
15.8.3 RECENT DEVELOPMENTS 121
15.9 CARGILL, INCORPORATED. 122
15.9.1 COMPANY SNAPSHOT 122
15.9.2 PRODUCT PORTFOLIO 122
15.9.3 RECENT DEVELOPMENTS 123
15.10 COLORCON 124
15.10.1 COMPANY SNAPSHOT 124
15.10.2 PRODUCT PORTFOLIO 124
15.10.3 RECENT DEVELOPMENTS 124
15.11 CRODA INTERNATIONAL PLC 126
15.11.1 COMPANY SNAPSHOT 126
15.11.2 REVENUE ANALYSIS 126
15.11.3 PRODUCT PORTFOLIO 127
15.11.4 RECENT DEVELOPMENTS 127
15.12 DFE PHARMA (SUBSIDIARY OF ROYAL FRIESLANDCAMPINA N.V) 129
15.12.1 COMPANY SNAPSHOT 129
15.12.2 REVENUE ANALYSIS 129
15.12.3 PRODUCT PORTFOLIO 130
15.12.4 RECENT DEVELOPMENTS 131
15.13 KERRY GROUP PLC. 132
15.13.1 COMPANY SNAPSHOT 132
15.13.2 REVENUE ANALYSIS 132
15.13.3 PRODUCT PORTFOLIO 133
15.13.4 RECENT DEVELOPMENTS 134
15.14 MEGGLE GMBH & CO. KG 135
15.14.1 COMPANY SNAPSHOT 135
15.14.2 PRODUCT PORTFOLIO 135
15.14.3 RECENT DEVELOPMENTS 136
15.15 OMYA AG 137
15.15.1 COMPANY SNAPSHOT 137
15.15.2 PRODUCT PORTFOLIO 137
15.15.3 RECENT DEVELOPMENTS 137
15.16 PETER GREVEN GMBH & CO. KG 138
15.16.1 COMPANY SNAPSHOT 138
15.16.2 PRODUCT PORTFOLIO 138
15.16.3 RECENT DEVELOPMENTS 138
15.17 PFANSTIEHL 140
15.17.1 COMPANY SNAPSHOT 140
15.17.2 PRODUCT PORTFOLIO 140
15.17.3 RECENT DEVELOPMENTS 140
16 QUESTIONNAIRE 141
17 RELATED REPORTS 144

ページTOPに戻る



図表リスト

LIST OF TABLES
TABLE 1 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2015-2029 (USD MILLION) 55
TABLE 2 NORTH AMERICA BINDERS AND ADHESIVES IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 56
TABLE 3 NORTH AMERICA DISINTEGRANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 56
TABLE 4 NORTH AMERICA COATING MATERIAL IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 57
TABLE 5 NORTH AMERICA COLORING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 58
TABLE 6 NORTH AMERICA SOLUBILIZERS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 58
TABLE 7 NORTH AMERICA FLAVORS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 59
TABLE 8 NORTH AMERICA SWEETENING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 60
TABLE 9 NORTH AMERICA DILUENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 60
TABLE 10 NORTH AMERICA LUBRICANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 61
TABLE 11 NORTH AMERICA BUFFERS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 62
TABLE 12 NORTH AMERICA EMULSIFYING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 62
TABLE 13 NORTH AMERICA PRESERVATIVES IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 63
TABLE 14 NORTH AMERICA ANTIOXIDANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 64
TABLE 15 NORTH AMERICA SORBENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 64
TABLE 16 NORTH AMERICA SOLVENTS PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 65
TABLE 17 NORTH AMERICA EMOLLIENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 65
TABLE 18 NORTH AMERICA GLIDENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 66
TABLE 19 NORTH AMERICA CHELATING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 67
TABLE 20 NORTH AMERICA ANTIFOAMING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 67
TABLE 21 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION) 72
TABLE 22 NORTH AMERICA SOLID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION) 73
TABLE 23 NORTH AMERICA SEMI-SOLID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION) 74
TABLE 24 NORTH AMERICA LIQUID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION) 75
TABLE 25 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY ROUTE OF ADMINISTRATION, 2015-2029 (USD MILLION) 79
TABLE 26 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL, 2015-2029 (USD MILLION) 84
TABLE 27 NORTH AMERICA DIRECT TENDER IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL, 2015-2029 (USD MILLION) 85
TABLE 28 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY END USER, 2015-2029 (USD MILLION) 89

　

ページTOPに戻る


　

Summary

North America pharmaceutical excipients market is projected to register a substantial CAGR of 6.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
North America Pharmaceutical Excipients Market, Functionality (Binders and Adhesives, Disintegrants, Coating Material, Disintegrants, Solubilizers, Flavors, Sweetening Agents, Diluents, Lubricants, Buffers, Emulsifying Agents, Preservatives, Antioxidants, Sorbents, Solvents, Emollients, Glidients, Chelating Agents, Antifoaming Agents, Others), Dosage Form (Solid, Semi-Solid, Liquid), Route of Administration (Oral Excipients, Topical Excipients, Parenteral Excipients, Other Excipients), End User (Pharmaceutical and Biopharmaceutical Companies, Contract Formulators, Research Organization and Academics, Others), Distribution Channel (Direct Tender, Retail Sales, Others) Geography (China, India, Japan, South Korea, Indonesia, Thailand, Vietnam, Philippines, Singapore, Malaysia, Australia, Rest of Asia Pacific)- Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the North America excipients market are:

• Innovations in biopharmaceuticals
• Increasing need for pharmaceutical products across varied therapeutic areas
Market Players:

The key market players operating in the North America Pharmaceutical Excipients market are listed below:
• DOW
• Roquette Frères
• JRS Pharma
• Evonik Industries AG
• The Lubrizol Corporation
• Kerry Group PLC
• Colorcon
• Ashland
• BASF SE



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET 14
1.4 LIMITATIONS 16
1.5 MARKETS COVERED 17
2 MARKET SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 21
2.4 CURRENCY AND PRICING 21
2.5 DBMR TRIPOD DATA VALIDATION MODEL 22
2.6 MULTIVARIATE MODELLING 25
2.7 FUNCTIONALITY LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 DBMR MARKET POSITION GRID 28
2.10 MARKET END USER COVERAGE GRID 29
2.11 VENDOR SHARE ANALYSIS 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHT 36
4.1 PESTEL 37
4.2 PORTER'S FIVE FORCES MODEL 38
4.3 INDUSTRIAL INSIGHTS: 39
5 NORTH AMERICA PHARMACEUTICAL EXCIPIENT MARKET: REGULATIONS 41
6 MARKET OVERVIEW 43
6.1 DRIVERS 45
6.1.1 RISE IN GENERIC DRUG PRODUCTION AND USES 45
6.1.2 THE SURGE IN DEMAND FOR EXCIPIENTS 45
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN MULTIFUNCTIONAL EXCIPIENTS 45
6.1.4 RISING FOCUS ON ORPHAN DRUGS 46
6.2 RESTRAINTS 46
6.2.1 INCREASING REGULATORY STRINGENCY REGARDING THE APPROVAL OF DRUGS AND EXCIPIENTS 46
6.2.2 HIGH PRODUCTION COST 47
6.3 OPPORTUNITIES 47
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 47
6.3.2 RISING DEMAND FOR EASE OF USE 48
6.3.3 RISING DISPOSABLE INCOME 48
6.3.4 INCREASING DEMAND FOR ALTERNATIVE ROUTES OF DELIVERY/DOSAGE FORMS 48
6.4 CHALLENGES 49
6.4.1 ASSOCIATED SIDE EFFECTS 49
6.4.2 SAFETY CONSIDERATION OF PHARMACEUTICAL EXCIPIENTS IN STORAGE & TRANSPORTATION 49
6.4.3 LACK OF NOVEL PHARMACEUTICAL EXCIPIENTS 50
7 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY 51
7.1 OVERVIEW 52
7.2 BINDERS AND ADHESIVES 55
7.2.1 ORGANIC 56
7.2.2 INORGANIC 56
7.3 DISINTEGRANTS 56
7.3.1 ORGANIC 56
7.3.2 INORGANIC 57
7.4 COATING MATERIAL 57
7.4.1 ORGANIC 57
7.4.2 INORGANIC 57
7.5 COLORING AGENTS 58
7.5.1 ORGANIC 58
7.5.2 INORGANIC 58
7.6 SOLUBILIZERS 58
7.6.1 ORGANIC 59
7.6.2 INORGANIC 59
7.7 FLAVORS 59
7.7.1 ORGANIC 59
7.7.2 INORGANIC 59
7.8 SWEETENING AGENTS 59
7.8.1 ORGANIC 60
7.8.2 INORGANIC 60
7.9 DILUENTS 60
7.9.1 ORGANIC 60
7.9.2 INORGANIC 60
7.10 LUBRICANTS 61
7.10.1 ORGANIC 61
7.10.2 INORGANIC 61
7.11 BUFFERS 61
7.11.1 ORGANIC 62
7.11.2 INORGANIC 62
7.12 EMULSIFYING AGENTS 62
7.12.1 ORGANIC 62
7.12.2 INORGANIC 62
7.13 PRESERVATIVES 63
7.13.1 ORGANIC 63
7.13.2 INORGANIC 63
7.14 ANTIOXIDANTS 63
7.14.1 ORGANIC 64
7.14.2 INORGANIC 64
7.15 SORBENTS 64
7.15.1 ORGANIC 64
7.15.2 INORGANIC 64
7.16 SOLVENTS 65
7.16.1 ORGANIC 65
7.16.2 INORGANIC 65
7.17 EMOLLIENTS 65
7.17.1 ORGANIC 65
7.17.2 INORGANIC 66
7.18 GLIDENTS 66
7.18.1 ORGANIC 66
7.18.2 INORGANIC 66
7.19 CHELATING AGENTS 66
7.19.1 ORGANIC 67
7.19.2 INORGANIC 67
7.20 ANTIFOAMING AGENTS 67
7.20.1 ORGANIC 67
7.20.2 INORGANIC 67
7.21 OTHERS 68
8 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM 69
8.1 OVERVIEW 70
8.2 SOLID 73
8.2.1 PLANT 73
8.2.2 ANIMALS 73
8.2.3 SYNTHETIC 73
8.2.4 MINERALS 73
8.3 SEMI-SOLID 73
8.3.1 PLANT 74
8.3.2 ANIMALS 74
8.3.3 SYNTHETIC 74
8.3.4 MINERALS 74
8.4 LIQUID 75
8.4.1 PLANT 75
8.4.2 ANIMALS 75
8.4.3 SYNTHETIC 75
8.4.4 MINERALS 75
9 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY ROUTE OF ADMINISTRATION 76
9.1 OVERVIEW 77
9.2 ORAL EXCIPIENTS 80
9.3 TOPICAL EXCIPIENTS 80
9.4 PARENTERAL EXCIPIENTS 80
9.5 OTHER EXCIPIENTS 80
10 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL 81
10.1 OVERVIEW 82
10.2 DIRECT TENDER 85
10.2.1 COMPANY TENDER 85
10.2.2 TENDER THROUGH MARCH MERCHANDISER 85
10.3 RETAIL SALES 85
10.4 OTHERS 85
11 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY END USER 86
11.1 OVERVIEW 87
11.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 90
11.3 CONTRACT FORMULATORS 90
11.4 RESEARCH ORGANIZATION 90
11.5 OTHERS 90
12 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION 91
12.1 U.S. 96
12.2 CANADA 96
12.3 MEXICO 96
13 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY LANDSCAPE 97
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 97
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 98
14 SWOT ANALYSIS 99
15 COMPANY PROFILE 100
15.1 DOW 100
15.1.1 COMPANY SNAPSHOT 100
15.1.2 REVENUE ANALYSIS 100
15.1.3 COMPANY SHARE ANALYSIS 101
15.1.4 PRODUCT PORTFOLIO 101
15.1.5 RECENT DEVELOPMENTS 101
15.2 ROQUETTE FRÈRES. 102
15.2.1 COMPANY SNAPSHOT 102
15.2.2 COMPANY SHARE ANALYSIS 102
15.2.3 PRODUCT PORTFOLIO 103
15.2.4 RECENT DEVELOPMENTS 104
15.3 EVONIK 105
15.3.1 COMPANY SNAPSHOT 105
15.3.2 REVENUE ANALYSIS 105
15.3.3 COMPANY SHARE ANALYSIS 106
15.3.4 PRODUCT PORTFOLIO 106
15.3.5 RECENT DEVELOPMENTS 106
15.4 THE LUBRIZOL CORPORATION 108
15.4.1 COMPANY SNAPSHOT 108
15.4.2 COMPANY SHARE ANALYSIS 108
15.4.3 PRODUCT PORTFOLIO 109
15.4.4 RECENT DEVELOPMENTS 109
15.5 BASF SE 110
15.5.1 COMPANY SNAPSHOT 110
15.5.2 REVENUE ANALYSIS 110
15.5.3 COMPANY SHARE ANALYSIS 111
15.5.4 PRODUCT PORTFOLIO 111
15.5.5 RECENT DEVELOPMENTS 112
15.6 ASHLAND (2021) 114
15.6.1 COMPANY SNAPSHOT 114
15.6.2 REVENUE ANALYSIS 114
15.6.3 PRODUCT PORTFOLIO 115
15.6.4 RECENT DEVELOPMENTS 116
15.7 AVANTOR, INC. 117
15.7.1 COMPANY SNAPSHOT 117
15.7.2 REVENUE ANALYSIS 117
15.7.3 PRODUCT PORTFOLIO 118
15.7.4 RECENT DEVELOPMENTS 119
15.8 BENEO 120
15.8.1 COMPANY SNAPSHOT 120
15.8.2 PRODUCT PORTFOLIO 120
15.8.3 RECENT DEVELOPMENTS 121
15.9 CARGILL, INCORPORATED. 122
15.9.1 COMPANY SNAPSHOT 122
15.9.2 PRODUCT PORTFOLIO 122
15.9.3 RECENT DEVELOPMENTS 123
15.10 COLORCON 124
15.10.1 COMPANY SNAPSHOT 124
15.10.2 PRODUCT PORTFOLIO 124
15.10.3 RECENT DEVELOPMENTS 124
15.11 CRODA INTERNATIONAL PLC 126
15.11.1 COMPANY SNAPSHOT 126
15.11.2 REVENUE ANALYSIS 126
15.11.3 PRODUCT PORTFOLIO 127
15.11.4 RECENT DEVELOPMENTS 127
15.12 DFE PHARMA (SUBSIDIARY OF ROYAL FRIESLANDCAMPINA N.V) 129
15.12.1 COMPANY SNAPSHOT 129
15.12.2 REVENUE ANALYSIS 129
15.12.3 PRODUCT PORTFOLIO 130
15.12.4 RECENT DEVELOPMENTS 131
15.13 KERRY GROUP PLC. 132
15.13.1 COMPANY SNAPSHOT 132
15.13.2 REVENUE ANALYSIS 132
15.13.3 PRODUCT PORTFOLIO 133
15.13.4 RECENT DEVELOPMENTS 134
15.14 MEGGLE GMBH & CO. KG 135
15.14.1 COMPANY SNAPSHOT 135
15.14.2 PRODUCT PORTFOLIO 135
15.14.3 RECENT DEVELOPMENTS 136
15.15 OMYA AG 137
15.15.1 COMPANY SNAPSHOT 137
15.15.2 PRODUCT PORTFOLIO 137
15.15.3 RECENT DEVELOPMENTS 137
15.16 PETER GREVEN GMBH & CO. KG 138
15.16.1 COMPANY SNAPSHOT 138
15.16.2 PRODUCT PORTFOLIO 138
15.16.3 RECENT DEVELOPMENTS 138
15.17 PFANSTIEHL 140
15.17.1 COMPANY SNAPSHOT 140
15.17.2 PRODUCT PORTFOLIO 140
15.17.3 RECENT DEVELOPMENTS 140
16 QUESTIONNAIRE 141
17 RELATED REPORTS 144

ページTOPに戻る



List of Tables/Graphs

LIST OF TABLES
TABLE 1 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2015-2029 (USD MILLION) 55
TABLE 2 NORTH AMERICA BINDERS AND ADHESIVES IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 56
TABLE 3 NORTH AMERICA DISINTEGRANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 56
TABLE 4 NORTH AMERICA COATING MATERIAL IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 57
TABLE 5 NORTH AMERICA COLORING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 58
TABLE 6 NORTH AMERICA SOLUBILIZERS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 58
TABLE 7 NORTH AMERICA FLAVORS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 59
TABLE 8 NORTH AMERICA SWEETENING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 60
TABLE 9 NORTH AMERICA DILUENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 60
TABLE 10 NORTH AMERICA LUBRICANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 61
TABLE 11 NORTH AMERICA BUFFERS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 62
TABLE 12 NORTH AMERICA EMULSIFYING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 62
TABLE 13 NORTH AMERICA PRESERVATIVES IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 63
TABLE 14 NORTH AMERICA ANTIOXIDANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 64
TABLE 15 NORTH AMERICA SORBENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 64
TABLE 16 NORTH AMERICA SOLVENTS PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 65
TABLE 17 NORTH AMERICA EMOLLIENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 65
TABLE 18 NORTH AMERICA GLIDENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 66
TABLE 19 NORTH AMERICA CHELATING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 67
TABLE 20 NORTH AMERICA ANTIFOAMING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION) 67
TABLE 21 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION) 72
TABLE 22 NORTH AMERICA SOLID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION) 73
TABLE 23 NORTH AMERICA SEMI-SOLID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION) 74
TABLE 24 NORTH AMERICA LIQUID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION) 75
TABLE 25 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY ROUTE OF ADMINISTRATION, 2015-2029 (USD MILLION) 79
TABLE 26 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL, 2015-2029 (USD MILLION) 84
TABLE 27 NORTH AMERICA DIRECT TENDER IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL, 2015-2029 (USD MILLION) 85
TABLE 28 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY END USER, 2015-2029 (USD MILLION) 89

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他（治療を主目的としない薬物））の最新刊レポート

Data Bridge Market Research 社の最新刊レポート

本レポートと同じKEY WORD（industry）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/10/01　10:26

145.10 円

161.88 円

196.72 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.